All In Biotech

Drug Trial Radar · NCT03586570

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, and Pharmacokinetics After Multiple-dose Administration of 25 mg Aprocitentan in Healthy Japanese and Caucasian Subjects

Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jul 17, 2018

Primary completion

Sep 10, 2018

Study completion Sep 10, 2018

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
Collaborators
Janssen Biotech, Inc.
First posted
Jul 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.

Conditions

  • Healthy Subjects

Interventions

  • Aprocitentan 25mgDrug

    Oral tablets in strength of 25 mg

  • PlaceboDrug

    Oral tablets matching aprocitentan tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax during the first and last dosing intervalTime frame: From study treatment administration to 216 hours after last administration
  2. Time to reach Cmax (tmax) during the first and last dosing intervalTime frame: From study treatment administration to 216 hours after last administration
  3. AUCτ on the first and last day of study treatment intakeTime frame: From study treatment administration to 216 hours after last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.